Topline data from the phase 3 E-BEOND and C-BEOND trials show a significant reduction in monthly migraine days at 24 weeks, demonstrating efficacy across the full migraine spectrum.
Experts discuss the bidirectional relationship between financial toxicity and cardiovascular disease outcomes in the US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results